Safety, pharmacokinetics and pharmacodynamics of <scp>BI</scp> 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 ( <scp>HSD1</scp> ) inhibitor in humans: liver and adipose tissue 11β‐ <scp>HSD1</scp> inhibition after acute and multiple administrations over 2 weeks

Abstract

BI 135585 was safe and well tolerated over 14 days and can be dosed once daily. Future studies are required to clarify the therapeutic potential of BI 135585 in view of its effects on 11β-HSD1 inhibition in AT after single and multiple doses. Enzyme inhibition in the AT was not adequately predicted by the urinary THF/THE ratio.